4.5 Article

The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future

期刊

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
卷 79, 期 2, 页码 182-194

出版社

WILEY
DOI: 10.1111/bcp.12403

关键词

adherence; antiretroviral; drug interactions; human immunodeficiency virus; pharmacogenomics; therapeutic drug monitoring

资金

  1. ViiV Healthcare
  2. Janssen
  3. Merck Pty Ltd
  4. Gilead
  5. AbbVie
  6. Bristol Myers Squibb

向作者/读者索取更多资源

The evolution of human immunodeficiency virus (HIV) treatment has improved our understanding and management of complex pharmacological issues that have driven improved outcomes and quality of life of the HIV-infected patient. These issues include adherence, long- and short-term toxicities, pharmacoenhancement, pharmacogenomics, therapeutic drug monitoring, differential penetration of drugs into sanctuary sites, such as the central nervous system, genital tract and small bowel, and drug-drug and drug-food interactions related to cytochrome P450 drug-metabolizing enzymes, uridine diphosphate glucuronyltransferases and drug transporters, to name a few. There is future promise, as an increased understanding of the immunopathogenesis of HIV and global public health initiatives are driving novel treatment approaches with goals to prevent, control and, ultimately, eradicate HIV.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据